NU 578 UNITS 1-5 EXAM - PHARMACOLOGY FOR ADVANCED PRACTICE
NURSES - UNIVERSITY OF SOUTH ALABAMA COLLEGE OF NURSING -
2026/2027 ACADEMIC YEAR - QUESTIONS AND ANSWERS COVERING
140 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Analyze pharmacokinetic and pharmacodynamic principles to optimize drug therapy
2 Evaluate drug interactions and adverse effects to ensure patient safety
3 Apply evidence-based guidelines to prescribe medications for common acute and chronic conditions
4 Modify pharmacotherapy based on patient-specific factors including organ function, genetics, and
pregnancy status
5 NU 578 Units 1
6 5 Exam
7 Pharmacology for Advanced Practice Nurses
8 University of South Alabama College of Nursing
9 2026
10 2027 Academic Year
11 Questions and Answers Covering Four Core Domains
12 Foundations of Pharmacology for Advanced Practice Nurses
13 Applied Pharmacology for Advanced Practice Nurses
14 Advanced Pharmacology for Advanced Practice Nurses
15 Pharmacology for Advanced Practice Nurses Review
ABSTRACT
Page 1
,This study document brings together 140 carefully worded exam questions drawn from NU 578
Units 1-5 Exam - Pharmacology for Advanced Practice Nurses - University of South Alabama
College of Nursing - 2026/2027 Academic Year - Questions and Answers Covering Four Core
Domains, with the strongest emphasis placed on Analyze pharmacokinetic and pharmacodynamic
principles to optimize drug therapy, Evaluate drug interactions and adverse effects to ensure
patient safety and Apply evidence-based guidelines to prescribe medications for common acute
and chronic conditions. Every item follows the wording style and level of reasoning you meet in the
real paper, and each one is paired with a clear rationale so the correct choice is never a guess.
Work through the set at your own pace, mark the questions that slow you down, then come back to
them until the reasoning feels automatic. Learners who revise this way walk into the exam room
recognising the pattern behind the questions instead of meeting them for the first time. Keep going
- steady, honest practice is what turns a difficult paper into a comfortable pass.
Q1 ANALYZE PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO OPTIMIZE
DRUG THERAPY
A patient with a history of chronic kidney disease (CrCl 25 mL/min) is started on a
medication that is primarily renally eliminated. The drug's half-life is prolonged.
Which pharmacokinetic parameter is most directly affected, and what is the most
appropriate initial action?
A. Decreased volume of distribution; increase the dose
B. Increased bioavailability; reduce the dose
C. Decreased clearance; extend the dosing interval CORRECT
D. Increased protein binding; monitor free drug levels
RATIONALE: In CKD, renal clearance of drugs is reduced, leading to prolonged half-life. The
most appropriate initial action is to extend the dosing interval to avoid accumulation. Other
options misidentify the parameter or suggest inappropriate actions.
Page 2
,Q2 ANALYZE PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO OPTIMIZE
DRUG THERAPY
A patient on warfarin is prescribed metronidazole for an infection. Which
mechanism best explains the increased INR observed?
A. Metronidazole displaces warfarin from albumin binding sites.
B. Metronidazole inhibits CYP2C9, reducing warfarin metabolism. CORRECT
C. Metronidazole induces CYP3A4, increasing warfarin clearance.
D. Metronidazole competes with warfarin for vitamin K epoxide reductase.
RATIONALE: Metronidazole is a potent inhibitor of CYP2C9, the enzyme responsible for
metabolizing the more potent S-enantiomer of warfarin, leading to increased INR. Displacement
from protein binding is transient and not the primary mechanism; induction would decrease INR,
and competition for the enzyme is not the mechanism.
Q3 ANALYZE PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO OPTIMIZE
DRUG THERAPY
A patient with type 2 diabetes and chronic kidney disease (eGFR 30 mL/min) needs
an antihyperglycemic agent. Which class is preferred due to cardiovascular and
renal benefit, and what monitoring is essential?
A. Sulfonylureas; monitor liver function tests
B. SGLT2 inhibitors; monitor renal function and volume status CORRECT
C. DPP-4 inhibitors; monitor pancreatic enzymes
D. Thiazolidinediones; monitor bone density
RATIONALE: SGLT2 inhibitors are preferred in patients with CKD and type 2 diabetes due to
cardiorenal protective effects, but they require monitoring of renal function and volume status,
especially when initiating. Sulfonylureas carry hypoglycemia risk, DPP-4 inhibitors are less
favored, and TZDs cause fluid retention.
Page 3
, Q4 ANALYZE PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO OPTIMIZE
DRUG THERAPY
A patient is taking digoxin and develops hypokalemia. Which change in digoxin
pharmacodynamics is expected?
A. Decreased sensitivity of Na+/K+-ATPase to digoxin
B. Increased risk of digoxin toxicity due to enhanced binding CORRECT
C. Reduced therapeutic effect because of electrolyte imbalance
D. No change in digoxin effect because potassium does not interact
RATIONALE: Hypokalemia increases the binding of digoxin to Na+/K+-ATPase, enhancing its
toxic effects, particularly cardiac arrhythmias. Potassium depletion sensitizes the myocardium to
digoxin, so toxicity risk is increased, not decreased.
Q5 ANALYZE PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO OPTIMIZE
DRUG THERAPY
A patient with a genetic variant causing poor CYP2D6 metabolism is prescribed
codeine for pain. What is the primary concern?
A. Lack of analgesic effect due to reduced conversion to morphine CORRECT
B. Increased risk of serotonin syndrome due to drug accumulation
C. Prolonged QT interval due to increased parent drug levels
D. Hepatotoxicity due to reactive metabolite formation
RATIONALE: Codeine is a prodrug that requires CYP2D6 to convert to morphine. Poor
metabolizers have reduced conversion, leading to inadequate analgesia. Ultrarapid metabolizers
are at risk of toxicity, but the question specifies poor metabolizers, making lack of effect the
primary concern.
Page 4
NURSES - UNIVERSITY OF SOUTH ALABAMA COLLEGE OF NURSING -
2026/2027 ACADEMIC YEAR - QUESTIONS AND ANSWERS COVERING
140 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Analyze pharmacokinetic and pharmacodynamic principles to optimize drug therapy
2 Evaluate drug interactions and adverse effects to ensure patient safety
3 Apply evidence-based guidelines to prescribe medications for common acute and chronic conditions
4 Modify pharmacotherapy based on patient-specific factors including organ function, genetics, and
pregnancy status
5 NU 578 Units 1
6 5 Exam
7 Pharmacology for Advanced Practice Nurses
8 University of South Alabama College of Nursing
9 2026
10 2027 Academic Year
11 Questions and Answers Covering Four Core Domains
12 Foundations of Pharmacology for Advanced Practice Nurses
13 Applied Pharmacology for Advanced Practice Nurses
14 Advanced Pharmacology for Advanced Practice Nurses
15 Pharmacology for Advanced Practice Nurses Review
ABSTRACT
Page 1
,This study document brings together 140 carefully worded exam questions drawn from NU 578
Units 1-5 Exam - Pharmacology for Advanced Practice Nurses - University of South Alabama
College of Nursing - 2026/2027 Academic Year - Questions and Answers Covering Four Core
Domains, with the strongest emphasis placed on Analyze pharmacokinetic and pharmacodynamic
principles to optimize drug therapy, Evaluate drug interactions and adverse effects to ensure
patient safety and Apply evidence-based guidelines to prescribe medications for common acute
and chronic conditions. Every item follows the wording style and level of reasoning you meet in the
real paper, and each one is paired with a clear rationale so the correct choice is never a guess.
Work through the set at your own pace, mark the questions that slow you down, then come back to
them until the reasoning feels automatic. Learners who revise this way walk into the exam room
recognising the pattern behind the questions instead of meeting them for the first time. Keep going
- steady, honest practice is what turns a difficult paper into a comfortable pass.
Q1 ANALYZE PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO OPTIMIZE
DRUG THERAPY
A patient with a history of chronic kidney disease (CrCl 25 mL/min) is started on a
medication that is primarily renally eliminated. The drug's half-life is prolonged.
Which pharmacokinetic parameter is most directly affected, and what is the most
appropriate initial action?
A. Decreased volume of distribution; increase the dose
B. Increased bioavailability; reduce the dose
C. Decreased clearance; extend the dosing interval CORRECT
D. Increased protein binding; monitor free drug levels
RATIONALE: In CKD, renal clearance of drugs is reduced, leading to prolonged half-life. The
most appropriate initial action is to extend the dosing interval to avoid accumulation. Other
options misidentify the parameter or suggest inappropriate actions.
Page 2
,Q2 ANALYZE PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO OPTIMIZE
DRUG THERAPY
A patient on warfarin is prescribed metronidazole for an infection. Which
mechanism best explains the increased INR observed?
A. Metronidazole displaces warfarin from albumin binding sites.
B. Metronidazole inhibits CYP2C9, reducing warfarin metabolism. CORRECT
C. Metronidazole induces CYP3A4, increasing warfarin clearance.
D. Metronidazole competes with warfarin for vitamin K epoxide reductase.
RATIONALE: Metronidazole is a potent inhibitor of CYP2C9, the enzyme responsible for
metabolizing the more potent S-enantiomer of warfarin, leading to increased INR. Displacement
from protein binding is transient and not the primary mechanism; induction would decrease INR,
and competition for the enzyme is not the mechanism.
Q3 ANALYZE PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO OPTIMIZE
DRUG THERAPY
A patient with type 2 diabetes and chronic kidney disease (eGFR 30 mL/min) needs
an antihyperglycemic agent. Which class is preferred due to cardiovascular and
renal benefit, and what monitoring is essential?
A. Sulfonylureas; monitor liver function tests
B. SGLT2 inhibitors; monitor renal function and volume status CORRECT
C. DPP-4 inhibitors; monitor pancreatic enzymes
D. Thiazolidinediones; monitor bone density
RATIONALE: SGLT2 inhibitors are preferred in patients with CKD and type 2 diabetes due to
cardiorenal protective effects, but they require monitoring of renal function and volume status,
especially when initiating. Sulfonylureas carry hypoglycemia risk, DPP-4 inhibitors are less
favored, and TZDs cause fluid retention.
Page 3
, Q4 ANALYZE PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO OPTIMIZE
DRUG THERAPY
A patient is taking digoxin and develops hypokalemia. Which change in digoxin
pharmacodynamics is expected?
A. Decreased sensitivity of Na+/K+-ATPase to digoxin
B. Increased risk of digoxin toxicity due to enhanced binding CORRECT
C. Reduced therapeutic effect because of electrolyte imbalance
D. No change in digoxin effect because potassium does not interact
RATIONALE: Hypokalemia increases the binding of digoxin to Na+/K+-ATPase, enhancing its
toxic effects, particularly cardiac arrhythmias. Potassium depletion sensitizes the myocardium to
digoxin, so toxicity risk is increased, not decreased.
Q5 ANALYZE PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO OPTIMIZE
DRUG THERAPY
A patient with a genetic variant causing poor CYP2D6 metabolism is prescribed
codeine for pain. What is the primary concern?
A. Lack of analgesic effect due to reduced conversion to morphine CORRECT
B. Increased risk of serotonin syndrome due to drug accumulation
C. Prolonged QT interval due to increased parent drug levels
D. Hepatotoxicity due to reactive metabolite formation
RATIONALE: Codeine is a prodrug that requires CYP2D6 to convert to morphine. Poor
metabolizers have reduced conversion, leading to inadequate analgesia. Ultrarapid metabolizers
are at risk of toxicity, but the question specifies poor metabolizers, making lack of effect the
primary concern.
Page 4
